The Experts below are selected from a list of 21840 Experts worldwide ranked by ideXlab platform
K Cambra - One of the best experts on this subject based on the ideXlab platform.
-
cutoff point for exhaled nitric oxide corresponding to 3 sputum eosinophils
Journal of Investigational Allergology and Clinical Immunology, 2015Co-Authors: M J Alvarezpuebla, Olaguibel Rivera Jm, E Almudevar, A A Echegoyen, De Esteban Chocarro B, K CambraAbstract:Background: The eosinophilic asthma phenotype (sputum eosinophils ≥3%) indicates a good response to corticosteroids and TH2 immunomodulators. Exhaled nitric oxide (FeNO) is rapidly measured by portable devices, and although it is not a Selective Marker of eosinophilic inflammation, several studies have demonstrated a strong correlation with it. We investigated which FeNO value was the best fit with 3% sputum eosinophils in asthma patients. Methods: We included 129 consecutive, nonsmoking asthmatics who underwent skin tests, FeNO quantification (NIOX MINO), spirometry, and induced sputum analysis and completed the Asthma Control Test questionnaire. Receiver operating characteristic curves were constructed, and logistic regression analysis was performed. Results: Symptoms were detected more frequently in the eosinophilic asthma group, as were higher airway obstruction and sensitivity to hypertonic saline. The FeNO cutoff point of 21 ppb was the best fit with 3% sputum eosinophilia. This value behaved better among corticosteroid-naive patients (sensitivity, 97%; specificity, 58%; positive predictive value, 86%; negative predictive value, 88%) than among those receiving corticosteroids (sensitivity, 81%; specificity, 25%; positive predictive value, 74%; negative predictive value, 33%). Conclusion: FeNO ≥21 ppb is associated with airway eosinophilia. In corticosteroid-naive patients, FeNO <21 ppb enables us to rule out airway eosinophilia.
-
cutoff point for exhaled nitric oxide corresponding to 3 sputum eosinophils
Journal of Investigational Allergology and Clinical Immunology, 2015Co-Authors: M J Alvarezpuebla, Olaguibel Rivera Jm, E Almudevar, A A Echegoyen, De Esteban Chocarro B, K CambraAbstract:Background: The eosinophilic asthma phenotype (sputum eosinophils ≥3%) indicates a good response to corticosteroids and TH2 immunomodulators. Exhaled nitric oxide (FeNO) is rapidly measured by portable devices, and although it is not a Selective Marker of eosinophilic inflammation, several studies have demonstrated a strong correlation with it. We investigated which FeNO value was the best fit with 3% sputum eosinophils in asthma patients. Methods: We included 129 consecutive, nonsmoking asthmatics who underwent skin tests, FeNO quantification (NIOX MINO), spirometry, and induced sputum analysis and completed the Asthma Control Test questionnaire. Receiver operating characteristic curves were constructed, and logistic regression analysis was performed. Results: Symptoms were detected more frequently in the eosinophilic asthma group, as were higher airway obstruction and sensitivity to hypertonic saline. The FeNO cutoff point of 21 ppb was the best fit with 3% sputum eosinophilia. This value behaved better among corticosteroid-naive patients (sensitivity, 97%; specificity, 58%; positive predictive value, 86%; negative predictive value, 88%) than among those receiving corticosteroids (sensitivity, 81%; specificity, 25%; positive predictive value, 74%; negative predictive value, 33%). Conclusion: FeNO ≥21 ppb is associated with airway eosinophilia. In corticosteroid-naive patients, FeNO <21 ppb enables us to rule out airway eosinophilia.
M J Alvarezpuebla - One of the best experts on this subject based on the ideXlab platform.
-
cutoff point for exhaled nitric oxide corresponding to 3 sputum eosinophils
Journal of Investigational Allergology and Clinical Immunology, 2015Co-Authors: M J Alvarezpuebla, Olaguibel Rivera Jm, E Almudevar, A A Echegoyen, De Esteban Chocarro B, K CambraAbstract:Background: The eosinophilic asthma phenotype (sputum eosinophils ≥3%) indicates a good response to corticosteroids and TH2 immunomodulators. Exhaled nitric oxide (FeNO) is rapidly measured by portable devices, and although it is not a Selective Marker of eosinophilic inflammation, several studies have demonstrated a strong correlation with it. We investigated which FeNO value was the best fit with 3% sputum eosinophils in asthma patients. Methods: We included 129 consecutive, nonsmoking asthmatics who underwent skin tests, FeNO quantification (NIOX MINO), spirometry, and induced sputum analysis and completed the Asthma Control Test questionnaire. Receiver operating characteristic curves were constructed, and logistic regression analysis was performed. Results: Symptoms were detected more frequently in the eosinophilic asthma group, as were higher airway obstruction and sensitivity to hypertonic saline. The FeNO cutoff point of 21 ppb was the best fit with 3% sputum eosinophilia. This value behaved better among corticosteroid-naive patients (sensitivity, 97%; specificity, 58%; positive predictive value, 86%; negative predictive value, 88%) than among those receiving corticosteroids (sensitivity, 81%; specificity, 25%; positive predictive value, 74%; negative predictive value, 33%). Conclusion: FeNO ≥21 ppb is associated with airway eosinophilia. In corticosteroid-naive patients, FeNO <21 ppb enables us to rule out airway eosinophilia.
-
cutoff point for exhaled nitric oxide corresponding to 3 sputum eosinophils
Journal of Investigational Allergology and Clinical Immunology, 2015Co-Authors: M J Alvarezpuebla, Olaguibel Rivera Jm, E Almudevar, A A Echegoyen, De Esteban Chocarro B, K CambraAbstract:Background: The eosinophilic asthma phenotype (sputum eosinophils ≥3%) indicates a good response to corticosteroids and TH2 immunomodulators. Exhaled nitric oxide (FeNO) is rapidly measured by portable devices, and although it is not a Selective Marker of eosinophilic inflammation, several studies have demonstrated a strong correlation with it. We investigated which FeNO value was the best fit with 3% sputum eosinophils in asthma patients. Methods: We included 129 consecutive, nonsmoking asthmatics who underwent skin tests, FeNO quantification (NIOX MINO), spirometry, and induced sputum analysis and completed the Asthma Control Test questionnaire. Receiver operating characteristic curves were constructed, and logistic regression analysis was performed. Results: Symptoms were detected more frequently in the eosinophilic asthma group, as were higher airway obstruction and sensitivity to hypertonic saline. The FeNO cutoff point of 21 ppb was the best fit with 3% sputum eosinophilia. This value behaved better among corticosteroid-naive patients (sensitivity, 97%; specificity, 58%; positive predictive value, 86%; negative predictive value, 88%) than among those receiving corticosteroids (sensitivity, 81%; specificity, 25%; positive predictive value, 74%; negative predictive value, 33%). Conclusion: FeNO ≥21 ppb is associated with airway eosinophilia. In corticosteroid-naive patients, FeNO <21 ppb enables us to rule out airway eosinophilia.
De Esteban Chocarro B - One of the best experts on this subject based on the ideXlab platform.
-
cutoff point for exhaled nitric oxide corresponding to 3 sputum eosinophils
Journal of Investigational Allergology and Clinical Immunology, 2015Co-Authors: M J Alvarezpuebla, Olaguibel Rivera Jm, E Almudevar, A A Echegoyen, De Esteban Chocarro B, K CambraAbstract:Background: The eosinophilic asthma phenotype (sputum eosinophils ≥3%) indicates a good response to corticosteroids and TH2 immunomodulators. Exhaled nitric oxide (FeNO) is rapidly measured by portable devices, and although it is not a Selective Marker of eosinophilic inflammation, several studies have demonstrated a strong correlation with it. We investigated which FeNO value was the best fit with 3% sputum eosinophils in asthma patients. Methods: We included 129 consecutive, nonsmoking asthmatics who underwent skin tests, FeNO quantification (NIOX MINO), spirometry, and induced sputum analysis and completed the Asthma Control Test questionnaire. Receiver operating characteristic curves were constructed, and logistic regression analysis was performed. Results: Symptoms were detected more frequently in the eosinophilic asthma group, as were higher airway obstruction and sensitivity to hypertonic saline. The FeNO cutoff point of 21 ppb was the best fit with 3% sputum eosinophilia. This value behaved better among corticosteroid-naive patients (sensitivity, 97%; specificity, 58%; positive predictive value, 86%; negative predictive value, 88%) than among those receiving corticosteroids (sensitivity, 81%; specificity, 25%; positive predictive value, 74%; negative predictive value, 33%). Conclusion: FeNO ≥21 ppb is associated with airway eosinophilia. In corticosteroid-naive patients, FeNO <21 ppb enables us to rule out airway eosinophilia.
-
cutoff point for exhaled nitric oxide corresponding to 3 sputum eosinophils
Journal of Investigational Allergology and Clinical Immunology, 2015Co-Authors: M J Alvarezpuebla, Olaguibel Rivera Jm, E Almudevar, A A Echegoyen, De Esteban Chocarro B, K CambraAbstract:Background: The eosinophilic asthma phenotype (sputum eosinophils ≥3%) indicates a good response to corticosteroids and TH2 immunomodulators. Exhaled nitric oxide (FeNO) is rapidly measured by portable devices, and although it is not a Selective Marker of eosinophilic inflammation, several studies have demonstrated a strong correlation with it. We investigated which FeNO value was the best fit with 3% sputum eosinophils in asthma patients. Methods: We included 129 consecutive, nonsmoking asthmatics who underwent skin tests, FeNO quantification (NIOX MINO), spirometry, and induced sputum analysis and completed the Asthma Control Test questionnaire. Receiver operating characteristic curves were constructed, and logistic regression analysis was performed. Results: Symptoms were detected more frequently in the eosinophilic asthma group, as were higher airway obstruction and sensitivity to hypertonic saline. The FeNO cutoff point of 21 ppb was the best fit with 3% sputum eosinophilia. This value behaved better among corticosteroid-naive patients (sensitivity, 97%; specificity, 58%; positive predictive value, 86%; negative predictive value, 88%) than among those receiving corticosteroids (sensitivity, 81%; specificity, 25%; positive predictive value, 74%; negative predictive value, 33%). Conclusion: FeNO ≥21 ppb is associated with airway eosinophilia. In corticosteroid-naive patients, FeNO <21 ppb enables us to rule out airway eosinophilia.
A A Echegoyen - One of the best experts on this subject based on the ideXlab platform.
-
cutoff point for exhaled nitric oxide corresponding to 3 sputum eosinophils
Journal of Investigational Allergology and Clinical Immunology, 2015Co-Authors: M J Alvarezpuebla, Olaguibel Rivera Jm, E Almudevar, A A Echegoyen, De Esteban Chocarro B, K CambraAbstract:Background: The eosinophilic asthma phenotype (sputum eosinophils ≥3%) indicates a good response to corticosteroids and TH2 immunomodulators. Exhaled nitric oxide (FeNO) is rapidly measured by portable devices, and although it is not a Selective Marker of eosinophilic inflammation, several studies have demonstrated a strong correlation with it. We investigated which FeNO value was the best fit with 3% sputum eosinophils in asthma patients. Methods: We included 129 consecutive, nonsmoking asthmatics who underwent skin tests, FeNO quantification (NIOX MINO), spirometry, and induced sputum analysis and completed the Asthma Control Test questionnaire. Receiver operating characteristic curves were constructed, and logistic regression analysis was performed. Results: Symptoms were detected more frequently in the eosinophilic asthma group, as were higher airway obstruction and sensitivity to hypertonic saline. The FeNO cutoff point of 21 ppb was the best fit with 3% sputum eosinophilia. This value behaved better among corticosteroid-naive patients (sensitivity, 97%; specificity, 58%; positive predictive value, 86%; negative predictive value, 88%) than among those receiving corticosteroids (sensitivity, 81%; specificity, 25%; positive predictive value, 74%; negative predictive value, 33%). Conclusion: FeNO ≥21 ppb is associated with airway eosinophilia. In corticosteroid-naive patients, FeNO <21 ppb enables us to rule out airway eosinophilia.
-
cutoff point for exhaled nitric oxide corresponding to 3 sputum eosinophils
Journal of Investigational Allergology and Clinical Immunology, 2015Co-Authors: M J Alvarezpuebla, Olaguibel Rivera Jm, E Almudevar, A A Echegoyen, De Esteban Chocarro B, K CambraAbstract:Background: The eosinophilic asthma phenotype (sputum eosinophils ≥3%) indicates a good response to corticosteroids and TH2 immunomodulators. Exhaled nitric oxide (FeNO) is rapidly measured by portable devices, and although it is not a Selective Marker of eosinophilic inflammation, several studies have demonstrated a strong correlation with it. We investigated which FeNO value was the best fit with 3% sputum eosinophils in asthma patients. Methods: We included 129 consecutive, nonsmoking asthmatics who underwent skin tests, FeNO quantification (NIOX MINO), spirometry, and induced sputum analysis and completed the Asthma Control Test questionnaire. Receiver operating characteristic curves were constructed, and logistic regression analysis was performed. Results: Symptoms were detected more frequently in the eosinophilic asthma group, as were higher airway obstruction and sensitivity to hypertonic saline. The FeNO cutoff point of 21 ppb was the best fit with 3% sputum eosinophilia. This value behaved better among corticosteroid-naive patients (sensitivity, 97%; specificity, 58%; positive predictive value, 86%; negative predictive value, 88%) than among those receiving corticosteroids (sensitivity, 81%; specificity, 25%; positive predictive value, 74%; negative predictive value, 33%). Conclusion: FeNO ≥21 ppb is associated with airway eosinophilia. In corticosteroid-naive patients, FeNO <21 ppb enables us to rule out airway eosinophilia.
E Almudevar - One of the best experts on this subject based on the ideXlab platform.
-
cutoff point for exhaled nitric oxide corresponding to 3 sputum eosinophils
Journal of Investigational Allergology and Clinical Immunology, 2015Co-Authors: M J Alvarezpuebla, Olaguibel Rivera Jm, E Almudevar, A A Echegoyen, De Esteban Chocarro B, K CambraAbstract:Background: The eosinophilic asthma phenotype (sputum eosinophils ≥3%) indicates a good response to corticosteroids and TH2 immunomodulators. Exhaled nitric oxide (FeNO) is rapidly measured by portable devices, and although it is not a Selective Marker of eosinophilic inflammation, several studies have demonstrated a strong correlation with it. We investigated which FeNO value was the best fit with 3% sputum eosinophils in asthma patients. Methods: We included 129 consecutive, nonsmoking asthmatics who underwent skin tests, FeNO quantification (NIOX MINO), spirometry, and induced sputum analysis and completed the Asthma Control Test questionnaire. Receiver operating characteristic curves were constructed, and logistic regression analysis was performed. Results: Symptoms were detected more frequently in the eosinophilic asthma group, as were higher airway obstruction and sensitivity to hypertonic saline. The FeNO cutoff point of 21 ppb was the best fit with 3% sputum eosinophilia. This value behaved better among corticosteroid-naive patients (sensitivity, 97%; specificity, 58%; positive predictive value, 86%; negative predictive value, 88%) than among those receiving corticosteroids (sensitivity, 81%; specificity, 25%; positive predictive value, 74%; negative predictive value, 33%). Conclusion: FeNO ≥21 ppb is associated with airway eosinophilia. In corticosteroid-naive patients, FeNO <21 ppb enables us to rule out airway eosinophilia.
-
cutoff point for exhaled nitric oxide corresponding to 3 sputum eosinophils
Journal of Investigational Allergology and Clinical Immunology, 2015Co-Authors: M J Alvarezpuebla, Olaguibel Rivera Jm, E Almudevar, A A Echegoyen, De Esteban Chocarro B, K CambraAbstract:Background: The eosinophilic asthma phenotype (sputum eosinophils ≥3%) indicates a good response to corticosteroids and TH2 immunomodulators. Exhaled nitric oxide (FeNO) is rapidly measured by portable devices, and although it is not a Selective Marker of eosinophilic inflammation, several studies have demonstrated a strong correlation with it. We investigated which FeNO value was the best fit with 3% sputum eosinophils in asthma patients. Methods: We included 129 consecutive, nonsmoking asthmatics who underwent skin tests, FeNO quantification (NIOX MINO), spirometry, and induced sputum analysis and completed the Asthma Control Test questionnaire. Receiver operating characteristic curves were constructed, and logistic regression analysis was performed. Results: Symptoms were detected more frequently in the eosinophilic asthma group, as were higher airway obstruction and sensitivity to hypertonic saline. The FeNO cutoff point of 21 ppb was the best fit with 3% sputum eosinophilia. This value behaved better among corticosteroid-naive patients (sensitivity, 97%; specificity, 58%; positive predictive value, 86%; negative predictive value, 88%) than among those receiving corticosteroids (sensitivity, 81%; specificity, 25%; positive predictive value, 74%; negative predictive value, 33%). Conclusion: FeNO ≥21 ppb is associated with airway eosinophilia. In corticosteroid-naive patients, FeNO <21 ppb enables us to rule out airway eosinophilia.
